Carta científica
Uso de rituximab para trombocitopenia refractaria en pacientes con anticuerpos antifosfolípidos
Rituximab therapy for refractory thrombocytopenia in patients with antiphospholipid antibodies
Felisa Vázquez Gómeza,
, María Prieto Arcea, Luis Ignacio González-Granadob, Eugenia Enríquez Merayoc, Jaime de Inocencio Arocenac
a Unidad de Hemato-Oncología Pediátrica, Hospital Universitario 12 de Octubre, Madrid, España
b Unidad de Inmunodeficiencias, Pediatría, Hospital Universitario 12 Octubre, Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid, España
c Unidad de Reumatología Pediátrica, Hospital Universitario 12 de Octubre, Madrid, España
Leído
12984
Vecesse ha leído el artículo
3265
Total PDF
9719
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 7 | 87 | 35 | 122 |
| 2025 6 | 124 | 55 | 179 |
| 2025 5 | 160 | 33 | 193 |
| 2025 4 | 115 | 36 | 151 |
| 2025 3 | 161 | 34 | 195 |
| 2025 2 | 137 | 27 | 164 |
| 2025 1 | 122 | 34 | 156 |
| 2024 12 | 108 | 42 | 150 |
| 2024 11 | 146 | 53 | 199 |
| 2024 10 | 141 | 34 | 175 |
| 2024 9 | 115 | 34 | 149 |
| 2024 8 | 164 | 52 | 216 |
| 2024 7 | 171 | 40 | 211 |
| 2024 6 | 133 | 33 | 166 |
| 2024 5 | 179 | 42 | 221 |
| 2024 4 | 147 | 62 | 209 |
| 2024 3 | 106 | 39 | 145 |
| 2024 2 | 157 | 30 | 187 |
| 2024 1 | 197 | 36 | 233 |
| 2023 12 | 261 | 29 | 290 |
| 2023 11 | 160 | 33 | 193 |
| 2023 10 | 126 | 31 | 157 |
| 2023 9 | 125 | 36 | 161 |
| 2023 8 | 111 | 23 | 134 |
| 2023 7 | 121 | 33 | 154 |
| 2023 6 | 127 | 35 | 162 |
| 2023 5 | 131 | 27 | 158 |
| 2023 4 | 97 | 17 | 114 |
| 2023 3 | 115 | 36 | 151 |
| 2023 2 | 81 | 28 | 109 |
| 2022 1 | 60 | 22 | 82 |
| 2022 12 | 90 | 32 | 122 |
| 2022 11 | 89 | 46 | 135 |
| 2022 10 | 84 | 50 | 134 |
| 2022 9 | 91 | 32 | 123 |
| 2022 8 | 81 | 53 | 134 |
| 2022 7 | 67 | 42 | 109 |
| 2022 6 | 75 | 44 | 119 |
| 2022 5 | 67 | 40 | 107 |
| 2022 4 | 58 | 34 | 92 |
| 2022 3 | 93 | 67 | 160 |
| 2022 2 | 96 | 31 | 127 |
| 2021 1 | 100 | 42 | 142 |
| 2021 12 | 124 | 53 | 177 |
| 2021 11 | 87 | 44 | 131 |
| 2021 10 | 153 | 79 | 232 |
| 2021 9 | 94 | 39 | 133 |
| 2021 8 | 86 | 53 | 139 |
| 2021 7 | 72 | 51 | 123 |
| 2021 6 | 86 | 39 | 125 |
| 2021 5 | 96 | 38 | 134 |
| 2021 4 | 230 | 150 | 380 |
| 2021 3 | 127 | 56 | 183 |
| 2021 2 | 110 | 27 | 137 |
| 2020 1 | 104 | 60 | 164 |
| 2020 12 | 101 | 31 | 132 |
| 2020 11 | 102 | 30 | 132 |
| 2020 10 | 156 | 29 | 185 |
| 2020 9 | 254 | 45 | 299 |
| 2020 8 | 86 | 25 | 111 |
| 2020 7 | 94 | 28 | 122 |
| 2020 6 | 90 | 32 | 122 |
| 2020 5 | 70 | 30 | 100 |
| 2020 4 | 80 | 16 | 96 |
| 2020 3 | 84 | 21 | 105 |
| 2020 2 | 72 | 19 | 91 |
| 2020 1 | 72 | 22 | 94 |
| 2019 12 | 79 | 27 | 106 |
| 2019 11 | 52 | 14 | 66 |
| 2019 10 | 68 | 18 | 86 |
| 2019 9 | 73 | 19 | 92 |
| 2019 8 | 69 | 19 | 88 |
| 2019 7 | 74 | 39 | 113 |
| 2019 6 | 84 | 22 | 106 |
| 2019 5 | 104 | 29 | 133 |
| 2019 4 | 108 | 48 | 156 |
| 2019 3 | 74 | 14 | 88 |
| 2019 2 | 74 | 15 | 89 |
| 2019 1 | 75 | 34 | 109 |
| 2018 12 | 72 | 33 | 105 |
| 2018 11 | 116 | 37 | 153 |
| 2018 10 | 84 | 25 | 109 |
| 2018 9 | 52 | 28 | 80 |
| 2018 8 | 3 | 0 | 3 |
| 2018 7 | 4 | 0 | 4 |
| 2018 6 | 9 | 0 | 9 |
| 2018 5 | 18 | 0 | 18 |
| 2018 4 | 42 | 0 | 42 |
| 2018 3 | 60 | 0 | 60 |
| 2018 2 | 43 | 0 | 43 |
| 2018 1 | 50 | 0 | 50 |
| 2017 12 | 57 | 0 | 57 |
| 2017 11 | 48 | 0 | 48 |
| 2017 10 | 53 | 0 | 53 |
| 2017 9 | 57 | 0 | 57 |
| 2017 8 | 54 | 1 | 55 |
| 2017 7 | 96 | 17 | 113 |
| 2017 6 | 61 | 47 | 108 |
| 2017 5 | 0 | 24 | 24 |
| 2017 4 | 0 | 17 | 17 |
| 2017 3 | 0 | 33 | 33 |
| 2017 2 | 0 | 13 | 13 |
| 2016 1 | 0 | 14 | 14 |
| 2016 12 | 0 | 13 | 13 |
| 2016 11 | 0 | 22 | 22 |
| 2016 10 | 0 | 12 | 12 |
Mostrar todo
